{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:03:46Z","timestamp":1749701026576,"version":"3.41.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson Services Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.02.007","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T23:58:47Z","timestamp":1739663927000},"page":"e457-e465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"25","author":[{"given":"Wee Joo","family":"Chng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Bin-Chia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy Kwang-Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-9049","authenticated-orcid":false,"given":"Aaron","family":"Springford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8272-797X","authenticated-orcid":false,"given":"Caitlin H","family":"Daly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10272","key":"10.1016\/j.clml.2025.02.007_bib0001","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clml.2025.02.007_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.clml.2025.02.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjbs.2023.103920","article-title":"An overview of multiple myeloma: a monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities","volume":"31","author":"Abduh","year":"2024","journal-title":"Saudi J Biol Sci"},{"issue":"1","key":"10.1016\/j.clml.2025.02.007_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010155","article-title":"How to manage patients with lenalidomide-refractory multiple myeloma","volume":"15","author":"de Arriba de la Fuente","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2025.02.007_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00ae insights: multiple myeloma, version 3.2022: featured updates to the NCCN Guidelines","volume":"20","author":"Callander","year":"2022","journal-title":"J Nat Comprehens Cancer Net"},{"issue":"2","key":"10.1016\/j.clml.2025.02.007_bib0006","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.clml.2025.02.007_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030963","article-title":"Lenalidomide in multiple myeloma: review of resistance mechanisms, current treatment strategies and future perspectives","volume":"15","author":"Kulig","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.clml.2025.02.007_bib0008","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.02.007_bib0009","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.02.007_bib0010","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.02.007_bib0011","unstructured":"ClinicalTrials.gov. Comparison of Pomalidomide and Dexamethasone with or without Daratumumab in subjects with relapsed or refractory multiple myeloma previously treated with lenalidomide and a proteasome inhibitor Daratumumab\/\u200bPomalidomide\/Dexamethasone vs Pomalidomide\/Dexamethasone (EMN14). Accessed May, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03180736."},{"key":"10.1016\/j.clml.2025.02.007_bib0012","unstructured":"ClinicalTrials.gov. Safety and efficacy of Pomalidomide, Bortezomib and low-dose Dexamethasone in subjects with relapsed or refractory multiple myeloma (OPTIMISMM). Accessed May, 2024. https:\/\/clinicaltrials.gov\/study\/NCT01734928."},{"key":"10.1016\/j.clml.2025.02.007_bib0013","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams K, Welton N NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016. Accessed May, 2024. https:\/\/www.nicedsu.org.uk."},{"issue":"10","key":"10.1016\/j.clml.2025.02.007_bib0014","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.clml.2025.02.007_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.clml.2025.02.007_bib0016","doi-asserted-by":"crossref","first-page":"43","DOI":"10.20982\/tqmp.03.2.p043","article-title":"Understanding power and rules of thumb for determining sample sizes","volume":"3","author":"Wilson Van Voorhis","year":"2007","journal-title":"TQMP"},{"issue":"1","key":"10.1016\/j.clml.2025.02.007_bib0017","first-page":"1","article-title":"brms: an R package for bayesian multilevel models using Stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Statistic Software"},{"key":"10.1016\/j.clml.2025.02.007_bib0018","unstructured":"Raju M, Aditya R, Seal B, et al. Real-world Prescribing Patterns in U.S. multiple Myeloma (MM) Patients Refractory to Lenalidomide in the front-line. Copenhagen, Denmark: European Haematology Association Congress; 2016."},{"key":"10.1016\/j.clml.2025.02.007_bib0019","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/01.HS9.0000846468.64341.f1","article-title":"P899: real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed\/refractory multiple myeloma from the optum database","volume":"6","author":"Dhakal","year":"2022","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.clml.2025.02.007_bib0020","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clml.2024.03.003","article-title":"Characteristics and outcomes of patients with relapsed\/refractory multiple myeloma after exposure to lenalidomide in first line of therapy: a single center database review in Greece","volume":"24","author":"Kastritis","year":"2024","journal-title":"Clin Lymph Myeloma Leuke"},{"issue":"1","key":"10.1016\/j.clml.2025.02.007_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100003","article-title":"Real-world comparison of daratumumab-based regimens in relapsed\/refractory multiple myeloma using health record data","volume":"1","author":"Derman","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"7","key":"10.1016\/j.clml.2025.02.007_bib0022","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/cancers13071631","article-title":"Multiple myeloma patients undergoing carfilzomib: development and validation of a risk score for cardiovascular adverse events prediction","volume":"13","author":"Astarita","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"34","key":"10.1016\/j.clml.2025.02.007_bib0023","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.2012.42.5967","article-title":"Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology","volume":"30","author":"Basch","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T03:22:04Z","timestamp":1749612124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000692"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}